Literature DB >> 9692694

Review article: faecal occult blood testing for colorectal cancer.

J E Allison1.   

Abstract

Major health organizations recommend colorectal cancer screening using faecal occult blood tests, sigmoidoscopy or both for patients 50 years of age or older who are at average risk for colorectal cancer. However, no specific recommendations have been made regarding choice of test from among the tests currently or soon to be available. Therefore, to aid clinicians in rationally choosing a particular test for faecal occult blood, published data are reviewed regarding the performance characteristics, strengths and weaknesses of the various faecal occult blood tests. New studies suggest that immunochemical tests (e.g. HemeSelect) or a combination of sensitive guaiac tests and immunochemical tests (e.g. Hemoccult Sensa and HemeSelect) are the most sensitive, specific tests for detecting colorectal carcinoma and colorectal polyps > or =1 cm.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9692694     DOI： 10.1046/j.1365-2036.1998.00231.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis.

Authors:  Alan S Rosman; Mark A Korsten
Journal:  J Gen Intern Med       Date:  2010-05-25       Impact factor: 5.128

2.  Faecal calprotectin levels in a high risk population for colorectal neoplasia.

Authors:  O Kronborg; M Ugstad; P Fuglerud; B Johne; J Hardcastle; J H Scholefield; K Vellacott; V Moshakis; J R Reynolds
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

3.  Prevalence of significant neoplasia in FOBT-positive patients on warfarin compared with those not on warfarin.

Authors:  Lulu Iles-Shih; Judy F Collins; Jennifer L Holub; David A Lieberman
Journal:  Am J Gastroenterol       Date:  2010-08-03       Impact factor: 10.864

4.  Prediction of flare-ups of ulcerative colitis using quantitative immunochemical fecal occult blood test.

Authors:  Motoaki Kuriyama; Jun Kato; Koji Takemoto; Sakiko Hiraoka; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

5.  Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).

Authors:  G Hoff; T Grotmol; E Thiis-Evensen; M Bretthauer; G Gondal; M H Vatn
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

6.  The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings.

Authors:  Salah H Elsafi; Norah I Alqahtani; Nawaf Y Zakary; Eidan M Al Zahrani
Journal:  Clin Exp Gastroenterol       Date:  2015-09-09

7.  Comparison of methods for fecal microbiome biospecimen collection.

Authors:  Christine Dominianni; Jing Wu; Richard B Hayes; Jiyoung Ahn
Journal:  BMC Microbiol       Date:  2014-04-23       Impact factor: 3.605

8.  Warfarin Use During Fecal Occult Blood Testing: A Meta-Analysis.

Authors:  Imran Ashraf; Shafaq Paracha; Saif-Ur-Rahman Paracha; Murtaza Arif; Abhishek Choudhary; Jonathan D Godfrey; Robert E Clark; Obai Abdullah; Michelle L Matteson; Srinivas R Puli; Jamal A Ibdah; Ousama Dabbagh; Matthew L Bechtold
Journal:  Gastroenterology Res       Date:  2012-03-20

9.  Colorectal cancer screening in an equal access healthcare system.

Authors:  Mia Debarros; Scott R Steele
Journal:  J Cancer       Date:  2013-03-20       Impact factor: 4.207
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.